Wantai Biotech announced that revenue for the first half of 2026 was 1,048 billion yuan, an increase of 24.29% over the previous year. Net profit loss attributable to shareholders of listed companies was 128 million yuan, compared with a loss of 144 million yuan for the same period last year. Loss of $169 million after deducting non-net profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.